MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 9.28 USD 2.2%
Market Cap: 1.4B USD
Have any thoughts about
MiMedx Group Inc?
Write Note

Net Margin
MiMedx Group Inc

23.9%
Current
-0.2%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.9%
=
Net Income
82m
/
Revenue
342.8m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
MiMedx Group Inc
NASDAQ:MDXG
1.3B USD
24%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-14%
Country US
Market Cap 1.3B USD
Net Margin
24%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.8B EUR
Net Margin
-14%
No Stocks Found

MiMedx Group Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

MiMedx Group Inc. is a fascinating player in the realm of life sciences, operating at the dynamic intersection of biotechnology and tissue engineering. Nestled in the healthcare sector, MiMedx specializes in developing and distributing regenerative biomaterials and allografts derived from human amniotic tissue. This niche focus allows the company to tap into the potential of natural biologics to promote effective healing and enhance patient outcomes, particularly in chronic and complex wound care. Their product offerings, which primarily include amniotic membrane and umbilical cord products, are harnessed to aid in tissue repair and to reduce inflammation and scarring, all of which are critical elements in successful clinical treatment. In terms of revenue generation, MiMedx's business model revolves around an intricate balance of innovation and strategic partnerships. By meticulously refining their proprietary processing techniques, the company maintains a competitive advantage that appeals to healthcare providers across various specialties, including orthopedics, podiatry, and reconstructive surgery. Revenue streams are predominantly driven by the sale of these biotechnology innovations to hospitals, healthcare providers, and through direct distribution channels. Further enhancing their financial robustness, MiMedx invests in extensive clinical trials and research, which underpin their marketing and educational efforts to broaden the adoption of their products. With a keen eye on developing medical solutions that cater to an aging population and a growing demand for effective wound care products, MiMedx positions itself as a crucial innovator in its sector.

MDXG Intrinsic Value
6.35 USD
Overvaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
23.9%
=
Net Income
82m
/
Revenue
342.8m
What is the Net Margin of MiMedx Group Inc?

Based on MiMedx Group Inc's most recent financial statements, the company has Net Margin of 23.9%.